Phase 2 study of CP-868,596 + docetaxel, AG-013736 [axitinib] + docetaxel, or CP-868,596 + AG-013736 + docetaxel and of docetaxel alone in patients with stage IIIb or IV non-small cell lung cancer

Trial Profile

Phase 2 study of CP-868,596 + docetaxel, AG-013736 [axitinib] + docetaxel, or CP-868,596 + AG-013736 + docetaxel and of docetaxel alone in patients with stage IIIb or IV non-small cell lung cancer

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 27 Oct 2015

At a glance

  • Drugs Crenolanib (Primary) ; Axitinib; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors AROG Pharmaceuticals
  • Most Recent Events

    • 06 Jun 2007 Status changed from initiated to withdrawn prior to recruitment. The study was cancelled before patient enrollment.
    • 26 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top